Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Yuzo Umeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5778-6863; OpenAlex author ID A5010475330. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 3 papers

Papers 21

  1. Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus. Co-author DOI 10.1016/j.omton.2026.201180↗
  2. p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Co-author DOI 10.1038/s41417-025-00989-3↗
  3. Microbiome Disturbance, Nutritional Vulnerability, and Treatment Tolerance in Pancreatic Ductal Adenocarcinoma: Mechanistic Links and Clinical Readiness. Last author DOI 10.3390/cancers18162658↗
  4. Novel modified frailty index predicts completion of adjuvant chemotherapy in resectable pancreatic cancer in a dual center study. Co-author DOI 10.1038/s41598-025-02365-5↗
  5. Long-term survival in a patient with postoperative pulmonary oligometastasis of pancreatic cancer treated with surgical resection and chemotherapy: A case repo… Co-author DOI 10.1097/md.0000000000043647↗
  6. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  7. Postoperative Geriatric Nutritional Risk Index as a Determinant of Tolerance to S-1 Adjuvant Chemotherapy After Curative Surgery for Pancreatic Ductal Adenocar… Last author DOI 10.3390/cancers17091448↗
  8. Nutritional Status and Chemotherapy Completion in Resectable Pancreatic Cancer: A Narrative Review. Last author DOI 10.3390/curroncol32090519↗
  9. C-Reactive Protein-to-Albumin Ratio as a Predictive Indicator for Evaluating Tolerability in S-1 Adjuvant Chemotherapy after Curative Surgery for Pancreatic Ca… Co-author DOI 10.3390/cancers16193372↗
  10. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00262-022-03334-x↗
  11. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. First author DOI 10.3390/jcm12020465↗
  12. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.09.003↗
  13. Feasibility of local therapy for recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.05.004↗
  14. A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. First author DOI 10.21873/anticanres.15523↗
  15. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2020.10.015↗
  16. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  17. Usefulness of Middle Colic Artery Transposition Technique for Hepatic Arterial Reconstruction in Conversion Surgery for an Initially Unresectable, Locally Adva… Co-author DOI 10.18926/amo/62410↗
  18. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2020.03.016↗
  19. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Co-author DOI 10.1007/s00535-019-01586-6↗
  20. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  21. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryuichi Yoshida · 13 shared papers, 2019–2026 · strength 2.05
  2. Toshiyoshi Fujiwara · 13 shared papers, 2017–2026 · strength 1.96
  3. Naotake Funamizu · 6 shared papers, 2024–2026 · strength 1.62
  4. Shinji Kuroda · 6 shared papers, 2020–2026 · strength 0.99
  5. Akimasa Sakamoto · 4 shared papers, 2024–2025 · strength 0.95
  6. Kosei Takagi · 5 shared papers, 2021–2025 · strength 0.88
  7. Yoshinori Kajiwara · 4 shared papers, 2022–2026 · strength 0.78
  8. Kazuya Yasui · 4 shared papers, 2021–2025 · strength 0.67
  9. Yasuo Nagai · 3 shared papers, 2025–2026 · strength 0.67
  10. Takeyoshi Nishiyama · 3 shared papers, 2025–2026 · strength 0.67
  11. Taku Aoki · 3 shared papers, 2024–2025 · strength 0.66
  12. Yasutsugu Takada · 3 shared papers, 2024–2025 · strength 0.66
  13. Ryohei Shoji · 3 shared papers, 2020–2026 · strength 0.58
  14. Kazuyuki Matsumoto · 3 shared papers, 2019–2025 · strength 0.38
  15. Hironari Kato · 3 shared papers, 2019–2025 · strength 0.38
  16. Tsunemichi Hirose · 1 shared paper, 2025 · strength 0.28
  17. Kazuhiro Yoshida · 2 shared papers, 2021–2022 · strength 0.28
  18. Hiroyuki Araki · 2 shared papers, 2020–2022 · strength 0.23
  19. Hiroyoshi Y. Tanaka · 1 shared paper, 2026 · strength 0.23
  20. Mitsunobu R. Kano · 1 shared paper, 2026 · strength 0.23
  21. Atsushi Masamune · 1 shared paper, 2026 · strength 0.23
  22. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  23. Yuki Fujii · 1 shared paper, 2025 · strength 0.19
  24. Kazuhiro Yoshida · 1 shared paper, 2025 · strength 0.19
  25. Motoyuki Otsuka · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.